SCHEMBL1019746

SCHEMBL1019746

Cc1ccc(S(=O)(=O)n2ccc3c(NC4CCCN(C(=O)OC(C)(C)C)C4)nc(Cl)nc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 3/20 0.43
▸ BCHE P06276 1/20 0.43
▸ BTK Q06187 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ MMP1 P03956 2/20 0.39
▸ MMP9 P14780 2/20 0.39
▸ MMP13 P45452 2/20 0.39
▸ PIM1 P11309 2/20 0.39
▸ PIM2 Q9P1W9 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ MMP3 P08254 1/20 0.38
▸ MMP7 P09237 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.38
▸ MERTK Q12866 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ BRD4 O60885 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448470 1.00 HTR6 (0.43) HTR6BCHEBTKCNR1CNR2
SCHEMBL22496878 1.00 HTR6 (0.43) HTR6BCHEBTKCNR1CNR2
SCHEMBL1018952 0.90 GPR119 (0.47) HTR6CNR1CNR2MMP13MEN1
SCHEMBL28587505 0.89 USP2 (0.40) HTR6MEN1KMT2AJAK2
SCHEMBL28587503 0.89 USP2 (0.40) HTR6MEN1KMT2AJAK2
SCHEMBL2728373 0.87 GPR119 (0.49) HTR6BCHEBTKMMP1MMP9
SCHEMBL6128886 0.87 GPR119 (0.49) HTR6BCHEBTKMMP1MMP9
SCHEMBL17545832 0.87 GPR119 (0.49) HTR6BCHEBTKMMP1MMP9
SCHEMBL17527469 0.85 GPR119 (0.49) HTR6BCHEBTKMMP1MMP9
SCHEMBL23878777 0.84 GPR119 (0.47) MMP13MEN1KMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109311896-B Pyrazolopyrimidine derivatives as kinase inhibitors 株式会社大熊制药 2021-08-24 — — CN disclosed
CN-113135920-A Pyrazolopyrimidine derivatives as kinase inhibitors 株式会社大熊制药 2021-07-20 — — CN disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 — — US disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 — — US disclosed
US-9139581-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-09-22 — — US disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 — — US disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 — — US disclosed
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-31 — — US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 — — US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 — — US disclosed
US-8258144-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-09-04 — — US disclosed
EP-2271631-A2 INHIBITORS OF PROTEIN KINASES Portola Pharmaceuticals, Inc. (US) 2011-01-12 — — EP disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 — — US disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 — — US disclosed
US-20090298823-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 — — US disclosed
WO-2009131687-A2 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2009-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029944-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK2 HTR6 3223/4885BCHE 4167/4885BTK 2/4885
US-20090298823-A1 Inhibitors of protein kinases SYK, BTK, JAK2 HTR6 3223/4885BCHE 4167/4885BTK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback